



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12P 19/26, C07H 5/04, A61K 31/725	A1	(11) International Publication Number: WO 96/14425 (43) International Publication Date: 17 May 1996 (17.05.96)
<p>(21) International Application Number: PCT/EP95/04241</p> <p>(22) International Filing Date: 30 October 1995 (30.10.95)</p> <p>(30) Priority Data: MI94A002240 4 November 1994 (04.11.94) IT</p> <p>(71) Applicant (for all designated States except US): INALCO S.P.A. [IT/IT]; Corso Venezia, 61, I-20121 Milan (IT).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): ZOPPETTI, Giorgio [IT/IT]; Via Mac Mahon, 43, I-20155 Milan (IT). ORESTE, Pasqua [IT/IT]; Via Mac Mahon, 43, I-20155 Milan (IT). CIPOLLETTI, Giovanni [IT/IT]; Via dei Fontanili, 4, I-20141 Milan (IT).</p> <p>(74) Agent: GERVASI, Gemma; Notarbartolo & Gervasi S.r.l., Viale Bianca Maria, 33, I-20122 Milan (IT).</p>	<p>(81) Designated States: AL, AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	

(54) Title: POLYSACCHARIDES HAVING A HIGH IDURONIC ACID CONTENT

(57) Abstract

Process for the preparation of polysaccharides having a high iduronic acid content comprising: a) N-deacetylation of the polysaccharide K5 from E. coli or of the heparan sulfate or O-desulfation of heparin or heparan sulfate; b) N-sulfation of the product obtained from the stage a); c) epimerization in presence of the C5 epimerase enzyme; d) sulfation of at least some free hydroxy groups, wherein the stage c) is carried out in a reaction medium constituted by a classical buffer solution formed by HEPES, potassium chloride, EDTA and TRITON X-100 to which a suitable additive is added.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgystan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

POLYSACCHARIDES HAVING A HIGH IDURONIC ACID CONTENT

PRIOR ART

The glycosaminoglycans which are substances obtained by extraction from animal tissues having various origin, for instance intestinal
5 mucosa, lung, etc. belong particularly to the class of the polysaccharides containing iduronic acid. Heparin, heparan sulfate, condroitin sulfates and hyaluronic acid belong to the family of glycosaminoglycans.

The various glycosaminoglycans have different chemical structures and
10 they are formed by polysaccharide chains constituted by the repetition of an uronic acid and a hexosamine. In particular in heparin and heparan sulfate the uronic acid is constituted by glycuronic or iduronic acid and the hexosamine by glycosamine.

The glycosamine may be preferentially N-acetylated (heparan sulfate)
15 or preferentially N-sulfated (heparin) and 6-O sulfated. Moreover a sulfate group may be found also in the position 3 of the glycosamine. The uronic acid may be 2-O sulfated.

The heparin has great importance in the clinical practice as anticoagulant and antithrombotic.

20 Besides this therapeutic use an useful utilization for the heparin and the heparan sulfate in several other pathologies, for instance with antilipemic, antiproliferative, antiviral, antitumoral and antiangiogenic function is expected.

The utilization of the heparin and the heparan sulfate in these new
25 therapeutic applications involves the necessity to obtain these

products, or similar products, by processes different from the extractive one, in particular by more flexible processes allowing the preparation of different structures.

Moreover the extractive process from animal tissues does not guarantee
5 to obtain a virus free product.

A process for the preparation of anticoagulant glycosaminoglycans by biosynthesis is described in the Patent Application No. WO 92/17507.

In this process the polysaccharide K5 from E. coli which is submitted to the following sequence of reactions:

- 10 - N-deacetylation;
 - N-sulfation;
 - epimerization in order to transform at least some residuals of D-glycuronic acid into residuals of L-iduronic acid; and
 - sulfation of at least some free hydroxy groups,
- 15 is used as a starting compound.

In this process the critical stage is constituted by the epimerization which is limited to a 20 % maximum. The epimerization is carried out at room temperature with two days duration in presence of the D-glycuronyl-L-iduronyl-C5-epimerase enzyme in a classical reaction
20 medium to pH 7.4 constituted by HEPES, potassium chloride, EDTA and TRITON X-100. An epimerization limited to one third of the uronic acid had been formerly described (M. Höök et al., The J. of Biol. Chem. 249, 12 3908-3915, June 25, 1974). And this epimerization degree seemed till now insuperable. Moreover it must be considered that in
25 this document the epimerization in cellular environment is described

in the murine mastocytoma in conditions in which every factor concerning the biosynthetic process is present.

However an epimerization degree as obtained from the known art does not allow to obtain a product with the requested characteristics for
5 the various therapeutic treatments.

In fact the iduronic acid gives a superior flexibility to the product with respect to the glycuronic acid (Casu B., Petitou M., Provasoli M., and Sinay P. (1988) Conformational flexibility: a new concept for explaining binding and biological properties of iduronic acid
10 containing glycosaminoglycans. Trends Biochem. Sci. 13, 221-225). It follows that the products containing high percentages of iduronic acid are more active with respect to those containing glycuronic acid as it is pointed out by the greater anticoagulant and antithrombotic activity of the heparin towards heparan sulfate and by other
15 activities such as that one on the basic fibroblast growth factor (bFGF) wherein the iduronic acid is recognized to be essential part of the active site (Maccarana M., Casu B., and Lindahl U. (1993). Minimal sequence in Heparin/Heparan Sulfate Required for Binding of Basic Fibroblast Growth Factor. J. Biol. Chem. 268, 23898-23905). Therefore
20 there is the problem to find a process allowing to obtain a product having a high degree of epimerization with yield and times acceptable according to the industrial point of view.

SUMMARY

We have found that polysaccharides having a high iduronic acid content
25 may be obtained starting from the polysaccharide K5 from E. coli or from heparin or from the heparan sulfate by a process comprising:

- a) N-deacetylation of said polysaccharide K5 or of the heparan sulfate or O-desulfation of the heparin or of the heparan sulfate;
 - b) N-sulfation of the product obtained from the stage a);
 - c) one or more treatments of epimerization in presence of the D-
5 glycuronyl-L-iduronyl-C5-epimerase enzyme;
 - d) sulfation of at least some free hydroxy groups, characterized in that the stage of epimerization is carried out in a reaction medium constituted by a classical buffer solution at pH 7.4 formed by HEPES, potassium chloride and EDTA to which TRITON X-100 and an additive, or
10 more additives, selected from the group formed by ethylene glycol, glycerol, polyvinylpyrrolidone, polyethylene glycol and phosphatidylcholine are added.
- Polysaccharides having iduronic acid content greater than 50% with respect to uronic acids total content are obtained by the process
15 according to the present invention.

DETAILED DESCRIPTION OF THE INVENTION

- The characteristics and the advantages of the process according to the present invention and of the obtained polysaccharides will be mostly pointed out during the following detailed description.
- 20 The polysaccharide K5 from E. coli described by Manzoni M., Bergomi S., Cavazzoni V. (Journal of Bioactive and Compatible Polymers. Vol. VIII, July 1993, 251-257) is a substance particularly suitable to the use as a starting material for the process according to the present invention.
 - 25 The heparin and the heparan sulfate may be used too as starting

material with some variation of the operative conditions of the first stages of the process.

The starting substances may have a molecular weight ranging from 2,000 to more than 50,000 D.

- 5 When the polysaccharide K5 is used its structure is modified first by N-deacetylation which is carried out by treatment with a mixture of hydrazine and hydrazine sulfate or in a basic environment with sodium hydroxide or potassium hydroxide.

Then one proceeds with the N-sulfation by treatment with
10 triethylamine-sulfur trioxide or with trimethylamine-sulfur trioxide. A variously N-sulfated product, for instance from 25% to 100%, may be obtained with these operations.

The reactions of N-deacetylation and N-sulfation are carried out according to the known techniques, for example according to the Patent
15 Application No. WO 92/17507.

When the heparin is used as starting substance first the O-desulfation and then the N-sulfation are carried out in order to resulfate the amino-positions which lost the sulfate groups during the O-desulfation.

- 20 When the heparan sulfate is used as starting substance both the N-deacetylation and the O-desulfation and the resulting N-resulfation are carried out.

The N-sulfated product obtained from the polysaccharide K5 or from the heparan sulfate as described above, is submitted to the epimerization
25 process in order to convert the glycuronic acid into iduronic acid while the product obtained from heparin is treated with the enzyme in

order to obtain the glycuronic acid from the iduronic acid.

The epimerization is carried out in presence of the D-glycuronyl-L-iduronyl-C5-epimerase enzyme (later on simply indicated with C5 epimerase) extracted from cattle liver and purified with the method
5 described by A. Malmström in J. B. C. 255, 3878-3883 (1980).

The Applicant has surprisingly found that modifying the classical reaction medium with suitable additives a very high degree of epimerization is obtained.

The reaction medium according to the present invention is a pH 7.4
10 buffer solution constituted by HEPES, potassium chloride, EDTA and TRITON X-100 and added with one or more additives selected from the group formed by ethylene glycol, glycerol, polyvinylpyrrolidone, particularly polyvinylpyrrolidone having molecular weight from 15,000 to 90,000, polyethylene glycol, and phosphatidylcholine in amounts
15 suitable to increase the buffer solution viscosity to values ranging from 1.1 to 3 centistokes.

In particular the reaction medium is prepared starting from the following buffer solution having pH 7.4: HEPES 0.04 M, KCl 0.4 M and EDTA 0.06 M, and to 25 ml of this buffer solution from 100 to 1000 μ l
20 of TRITON X-100, from 0.5 ml to 60 ml of additive and distilled water to 100 ml are added.

The polysaccharide to submit to epimerization is added to said reaction medium in an amount from 5 to 1000 mg per 100 ml obtaining the solution A.

25 The C5 epimerase is separately dissolved in the same above-mentioned

reaction medium in amounts from 21 to 2000 µg per 100 ml obtaining the solution B.

The solution B is added to the solution A in such a proportion to obtain a content from 1.5 to 15.000 µg of C5 epimerase per 100 ml of
5 mixture to submit to epimerization. The mixture is homogenized by agitation and warmed at a temperature ranging from 30 to 40 °C in a constant-temperature chamber for a time ranging from 90 minutes to 15 hours.

The reaction is stopped warming the mixture at 100 °C for 5 minutes.

10 The product is purified through a DEAE-Sephacel column using $(\text{NH}_4)\text{HCO}_3$ 0.05 M as buffer and eluting the product with $(\text{NH}_4)\text{HCO}_3$ 2M buffer.

The gathered fractions are desalted by Sephadex G-15 column, the fraction containing the product is lyophilized and the product is analyzed by $^1\text{H-NMR}$.

15 The content of D-glycuronic acid and of the L-iduronic acid is computed by $^1\text{H-NMR}$ spectrum. The product obtained can be redissolved in solution A and treated again with solution B obtaining, with further treatments of epimerization, an increase of the L-iduronic acid content.

20 In order to estimate the anticoagulant and antithrombotic activity, the epimerized product is O-sulfated using pyridine-sulfur trioxide as sulfating agent for instance with the method described by Ogamo et al. in the abstracts of the XIV International Carbohydrate Symposium (August 14-19, 1988), Stockholm. The products of the Examples 1, 3, 4,
25 5, 6, 7 and 9, obtained with the process according to the present invention, as later on reported, submitted to O-sulfation, have shown

an excellent anticoagulant and antithrombotic activity while the products of the Examples 2 and 8, obtained according to the known technique, has shown much lower activity.

The obtained results show that the products according to the present invention have characteristics suitable to the clinical use with
5 anticoagulant and antithrombotic function and therefore they may be used for the preparation of the pertaining pharmaceutical compositions mixed with adjuvant and excipient substances.

In order to explain the process according to the present invention the
10 following examples are reported.

EXAMPLE 1

A buffer solution containing 0.04 M HEPES, 0.06 M EDTA, 0.4 M KCl pH 7.4 was prepared and 27 μ l of TRITON X-100, 9 ml of 10% polyvinylpyrrolidone K15 in water, 1.62 ml of ethylene glycol and
15 water to a total volume of 18 ml were added to 4.5 ml of this solution.

The solution showed a viscosity of 1.41 centistokes. In this solution 1 mg of 100% N-deacetylated N-sulfated K5 was dissolved obtaining solution A.

20 1.6 ml of 10% polyvinylpyrrolidone K15 in water, 288 μ l of ethylene glycol and water to a total volume of 3.2 ml were added to 0.8 ml of the same starting buffer solution pH 7.4 containing 8.9 μ g of C5 epimerase, obtaining solution B.

Solution A was mixed with 1.6 ml of solution B and the mixture was
25 kept at 37°C for 4 hours in a warm room. After 4 hours, 1.6 ml of

solution B were added and the reaction was kept at 37°C overnight.

The reaction was stopped by heating at 100°C for 5 minutes.

The product was purified by a DEAE-Sephacel column (2 x 1.5 cm) using 0.05 M (NH₄)HCO₃ as buffer and the product was eluted with 2 M

5 (NH₄)HCO₃.

The fractions containing the product were desalted on a Sephadex G-15 column (0.3 x 5 cm) and freeze-dried.

The product was analysed by 1H-NMR and the spectrum is shown in Fig. 1.

10 The percentage of L-iduronic acid over the total uronic acids was 55.

EXAMPLE 2 (Comparison)

The Example 1 has been repeated with the difference that the polyvinylpyrrolidone and the ethylene glycol have not been added.

The used buffer solution had a viscosity about equal to the water,
15 namely about zero.

The 1H-NMR spectrum relative to the obtained product is reported in the fig. 2. The L-iduronic acid content with reference to the sum of the iduronic acid and the glycuronic acid turned out to be equal to 18% .

20 EXAMPLE 3

The Example 1 has been repeated with the difference that the N-deacetylated and 50% N-sulfated polysaccharide K5 has been used as starting substance.

The obtained product has been analyzed by 1H-NMR and the relative
25 spectrum is reported in the Fig. 3.

The L-iduronic acid content turned out to be equal to 51% with

reference to the total of the uronic acids local to a N-sulfated glucosamine.

EXAMPLE 4

0.06 M EDTA, 0.4 M KCl pH 7.4, 30 μ l of TRITON X-100, 10.6 ml of 10%
5 polyvinylpyrrolidone K15 in water, 0.85 ml of ethylene glycol and 4.42 ml of water were added to 5.3 ml of a buffer solution containing 0.04 M HEPES.

The solution showed a viscosity of 1.2 centistokes.

2 mg of 100% N-deacetylated N-sulfated K5 were dissolved in 9 ml of
10 this solution, obtaining solution A.

1.7 μ g of C5 epimerase were dissolved in 8 ml of the same solution obtaining solution B.

Solutions A and B were mixed and the mixture was kept at 37°C for 4 hours in a warm room. The reaction was stopped by heating at 100°C for
15 5 minutes.

The product was purified as described in Example 1.

After freeze-drying the purified product was dissolved in 1 ml of solution A and mixed with 3.2 ml of solution B containing 8.9 μ g of C5 epimerase.

20 The mixture was kept at 37°C overnight and the enzyme was inactivated by heating at 100°C for 5 minutes. The product was purified as described in Example 1 and analysed by ¹H-NMR as shown in Fig. 4.

The percentage of L-iduronic acid over the total uronic acids was 53.

EXAMPLE 5

25 A buffer solution containing 0.04 M HEPES, 0.06 M EDTA, 0.4 M KCl pH

7.4 was prepared and 22.8 μ l of TRITON X-100, 1 mg of 100% N-deacetylated, N-sulfated K5, 4 ml of a solution of 20% polyvinylpyrrolidone K15 containing 40% ethylene glycol and water to a total volume of 8 ml were added to 2 ml of this solution. 6 ml of a
5 solution containing 0.01 M HEPES, 0.015 M EDTA, 0.01 M KCl, 0.015% TRITON X-100 and 134.4 μ g of C5 epimerase were added to 6 ml of this solution.

The solution obtained showed a viscosity of 1.36 centistokes.

The mixture was kept at 37°C for 1 hour. The reaction was stopped by
10 boiling at 100°C for 5 minutes.

The product was purified as described in Example 1.

After freeze-drying the product was dissolved in buffer solution containing 6.25 ml of 0.04 M HEPES, 0.06 M EDTA, 0.4 M KCl pH 7.4, 2.5 g of polyvinylpyrrolidone K15, 2.5 ml of ethylene glycol, 71.2 μ l of
15 TRITON X-100 and water to a total volume of 25 ml.

1.9 μ g of C5 epimerase dissolved in 12 ml of 0.01 M HEPES, 0.015 M EDTA, 0.1 M KCl pH 7.4 containing 0.015% of TRITON X-100 were added to 12 ml of the obtained mixture.

The mixture showed a viscosity of 1.4 centistokes.

20 The reaction was kept at 37°C overnight. At the end of the reaction the enzyme was inactivated by heating the solution at 100°C for 5 minutes. The product was purified as described in example 1 and the ¹H-NMR spectrum was performed (Fig. 5).

The percentage of L-iduronic acid over the total uronic acids was 52.

25 EXAMPLE 6

The Example 5 was repeated except that in the first step the reaction

was kept at 37°C for 4 hours.

After purification in the same conditions of Example 1 and after freeze-drying the product was dissolved in 1 ml of water and added to a buffer solution containing 50 ml of 0.04 M HEPES, 0.06 M EDTA, 0.4 M
5 KCl pH 7.4, 283.5 µl of TRITON X-100, 100 ml of 10% polyvinylpyrrolidone K15, 20 ml of ethylene glycol, 2 ml of 90% glycerol, 1.9 µg of C5 epimerase and water to a total volume of 200 ml. The mixture showed a viscosity of 1.41 centistokes.

The reaction was kept at 37°C for 4 hours and the enzyme was
10 inactivated at 100 °C for 5 minutes.

The product was purified as described in Example 1 and the 1H-NMR spectrum was performed (Fig. 6).

The percentage of L-iduronic acid over the total uronic acids was 55.

EXAMPLE 7

15 1.5 mg of 100% N-deacetylated, N-sulfated K5 were dissolved in a buffer solution containing 7 ml of 0.04 M HEPES, 0.06 M EDTA, 0.4 M KCl pH 7.4, 210 µl of TRITON X-100, 1.4 g of polyvinylpyrrolidone K15, 2.8 ml of ethylene glycol, 1.5 mg of C5 epimerase and water to a total volume of 28 ml.

20 The solution showed a viscosity of 1.36 centistockes.

The reaction was kept at 37°C for 4 hours and the enzyme was inactivated at 100°C for 5 minutes.

The product was purified as described in Example 1 and freeze-dried.

The product was then dissolved in 24 ml of the same solution
25 containing 1.3 mg of C5 epimerase and the reaction was kept at 37°C

for 4 hours and the enzyme was inactivated at 100°C for 5 minutes.

The product was purified as described in Example 1 and freeze-dried.

The product was then dissolved in 8.4 ml of the same solution containing 1 mg of C5 epimerase and the reaction was kept at 37°C for
5 4 hours.

The product was purified as described in Example 1 and the 1H-NMR spectrum was performed (Fig. 7).

The percentage of L-iduronic acid over the total uronic acids was 80.

EXAMPLE 8 (comparison)

10 1 mg of 100% N-deacetylated, N-sulfated K5 was dissolved in a buffer solution containing 3 ml of 0.04 M HEPES, 0.06 M EDTA, 0.4 M KCl pH 7.4, 18 µl of TRITON X-100, 1.2 ml of acetone, 1.9 µg of C5 epimerase and water to a total volume of 12 ml.

The solution showed a viscosity of 0.09 centistokes.

15 The reaction was kept at 37°C for 4 hours.

The product was purified as described in Example 1 and the 1H-NMR spectrum was performed (Fig. 8).

The percentage of L-iduronic acid over the total uronic acids was 0.

EXAMPLE 9

20 1 mg of 100% N-deacetylated, N-sulfated K5 was dissolved in a buffer solution containing 2 ml of 0.04 M HEPES, 0.06 M EDTA, 0.4 M KCl pH 7.4, 12 µl of TRITON X-100, 1.336 ml of 2.4% polyvinylpyrrolidone K90, 304 µg of C5 epimerase and water to a total volume of 8 ml.

The solution showed a viscosity of 1.29 centistokes.

25 The reaction was kept at 37°C for 4 hours, the enzyme was inactivated at 100°C for 5 minutes and the solution filtered in a 0.22 µm device.

8 ml of the same mixture containing 304 μg of C5 epimerase were added to the filtered solution and the reaction was kept at 37°C for 4 hours, the enzyme was inactivated at 100°C for 5 minutes and the solution filtered in a 0.22 μm device.

- 5 8 ml of the same mixture containing 304 μg of C5 epimerase were added to this solution and the reaction was kept at 37°C for 4 hours, the enzyme was inactivated at 100°C for 5 minutes and the solution filtered in a 0.22 μm device.

The product was purified as described in Example 1 and the $^1\text{H-NMR}$
10 spectrum was performed (Fig. 9).

The percentage of L-iduronic acid over the total uronic acids was 59.

CLAIMS

- 1 1. Process for the preparation of polysaccharides having a L-iduronic
2 acid content greater than 50% with reference to the uronic acids total
3 content starting from the polysaccharide K5 of the E. coli or from the
4 heparin or the heparan sulfate comprising:
- 5 a) N-deacetylation of said polysaccharide K5 or of the heparan sulfate
6 or O-desulfation of said heparin or heparan sulfate;
- 7 b) N-sulfation of the product obtained from the stage a);
- 8 c) one or more treatments of epimerization in presence of the C5
9 epimerase enzyme;
- 10 d) sulfation of at least some free hydroxy groups, characterized in
11 that the epimerization stage is carried out in a reaction medium
12 consisting of a classical buffer solution at pH 7.4 constituted by
13 HEPES, potassium chloride and EDTA to which TRITON X-100 and an
14 additive or more additives in an amount suitable to increase the
15 viscosity of said buffer solution to values ranging from 1.1 to 3
16 centistokes are added.
- 1 2. Process as claimed in claim 1, characterized in that said additives
2 are selected from the group consisting of ethylene glycol, glycerol,
3 polyvinylpyrrolidone, polyethylene glycol and phosphatidylcholine.
- 1 3. Process as claimed in claim 1, characterized in that said additive
2 is polyvinylpyrrolidone having molecular weight from 15,000 to 90,000.
- 1 4. Process as claimed in claim 1, characterized in that said additive,
2 or additives, are added to said buffer solution in an amount from 2 to
3 240 ml with reference to 100 ml of said buffer solution.
- 1 5. Process as claimed in claim 1, characterized in that said starting

2 compound is dissolved in said reaction medium in an amount from 5 to
3 1000 mg per 100 ml.

1 6. Process as claimed in claim 1, characterized in that said C5
2 epimerase is dissolved in said reaction medium in an amount from 21 to
3 2000 µg per 100 ml.

1 7. Process as claimed in claim 1, characterized in that the mixture
2 for the epimerization contains from 1.5 to 15,000 µg of C5 epimerase
3 per 100 ml of the mixture.

1 8. Process as claimed in claim 1, characterized in that said
2 epimerization reaction is carried out in a constant-temperature
3 chamber at a temperature ranging from 30 to 40 °C.

1 9. Process as claimed in claim 1, characterized in that said starting
2 product is N-sulfated from 25% to 100%.

1 10. Polysaccharides characterized in that they have a L-iduronic acid
2 content greater than 50% with reference to the uronic acid total
3 content, obtained with the process as claimed in claim 1.

1 11. Use of the polysaccharides as claimed in claim 10 for the
2 preparation of pharmaceutical compositions having anticoagulant and
3 antithrombotic activity.




FIG. 1

FIG. 2




FIG. 3





FIG. 4







FIG. 5

FIG. 6



7/9

FIG. 7






FIG. 8



9/9

FIG. 9



INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 95/04241

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12P19/26 C07H5/04 A61K31/725

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C12P C07H A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO,A,92 17507 (ITALFARMACO S.P.A.) 15 October 1992 cited in the application see the whole document ---	1-9
X	TRENDS BIOCHEM. SCI., vol. 13, 1988 pages 221-225, CASU ET AL. 'Confirmational Flexibility' cited in the application see page 221, column 3 ---	10,11
	-/--	

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

21 March 1996

Date of mailing of the international search report

10. 04.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Douschan, K

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 95/04241

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	J. BIOL. CHEM., vol. 268, no. 32, 1993 pages 23898-23905, MACCARANA ET AL. 'Minimal Sequence in Heparin Heparan Sulfate Required for Binding of Basic Fibroblast Growth Factor' cited in the application see page 23898, column 2 ---	10,11
X	CHEMICAL ABSTRACTS, vol. 115, no. 17, 1991 Columbus, Ohio, US; abstract no. 180062w, see abstract & BIOCHEM. J., vol. 276, no. 2, 1991 pages 533-539, COESTER ET AL. 'Biosynthesis of Dermatan Sulfate Proteoglycans' -----	10,11

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP 95/04241

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9217507	15-10-92	GB-A- 2254083	30-09-92
		AU-B- 1430892	02-11-92
		EP-A- 0577665	12-01-94
		GB-A- 2286193	09-08-95
		HU-A- 67208	28-02-95
		IT-B- 1254564	25-09-95
		JP-T- 7501684	23-02-95
		ZA-A- 9202313	02-08-93
